Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Marriott Wardman Park Hotel

27 ene 2020 7:00 a.m. - 29 ene 2020 4:15 p.m.

2660 Woodley Road, NW, , Washington, DC 20008 , USA

Pharmacovigilance and Risk Management Strategies Conference

Session 3: Drug Induced Liver Injury (DILI)

Session Chair(s)

Lesley  Wise, PhD, MSc

Lesley Wise, PhD, MSc

Managing Director

Wise Pharmacovigilance and Risk Management, Ltd, United Kingdom

Drug Induced Liver Injury is a potentially serious ADR. This session will provide an overview of the current research and assessment process for DILI from the president of CIOMS, pharmacology professor and hepatologist Professor Hervé Le-Louet.

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Understand the main ways that drugs can cause DILI
  • Understand the limitations of non-clinical and clinical research in predicting DILI
  • Learn about the current research into DILI

Speaker(s)

Hervé  Le Louet, DrMed, DrSc, MD, PhD, MS

Update from CIOMS on Current Developments in DILI

Hervé Le Louet, DrMed, DrSc, MD, PhD, MS

CIOMS, Switzerland

President

Arie  Regev, MD

Principles of Detection and Characterization of DILI

Arie Regev, MD

Eli Lilly and Company , United States

Chair, Liver and GI Safety Committee

Mark  Avigan, MD

DILI Risk Assessment and Risk Stratification in Clinical Trials and Post-Marketing

Mark Avigan, MD

FDA, United States

Associate Director for Critical Path Initiatives, OPE, OSE, CDER

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.